Person:
YÜKSEL MAYDA, PELİN

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
Job Title
First Name
PELİN
Last Name
YÜKSEL MAYDA
Name
Email Address
Birth Date

Search Results

Now showing 1 - 5 of 5
  • PublicationOpen Access
    Neopterin and Soluble CD14 Levels as Indicators of Immune Activation in Cases with Indeterminate Pattern and True Positive HIV-1 Infection.
    (2016-03-31) UYSAL, HARUN; SOHRABI, P; HABIP, Z; SARIBAS, S; KOCAZEYBEK, E; SEYHAN, F; CALıŞKAN, R; BONABI, E; YUKSEL, PELİN; BIRINCI, I; Uysal, O; KOCAZEYBEK, B; YÜKSEL MAYDA, PELİN; UYSAL, ÖMER
    Background: We aimed to evaluate the roles of the plasma immune activation biomarkers neopterin and soluble CD14 (sCD14) in the indirect assessment of the immune activation status of patients with the indeterminate HIV-1 (IHIV-1) pattern and a true HIV-1-positive infection (PCG). Methods: This cross-sectional and descriptive study included eighty-eight patients with the IHIV-1 pattern, 100 patients in the PCG, and 100 people in a healthy control group (HCG). Neopterin and sCD14 levels were determined by competitive and sandwich ELISA methods, respectively. Results: Mean neopterin and sCD14 levels among those with the IHIV-1 pattern were significantly lower than among the PCG (p < 0.001 and p = 0.001, respectively), but they were similiar to those in the HCG (p = 0.57 and p = 0.66, respectively. Mean neopterin and sCD14 levels among the PCG were found to be significantly higher than among those with the IHIV-1 pattern (p < 0.001 and p = 0.001, respectively) and among those in the HCG (p = 0.001, p < 0.001, respectively). Neopterin did not have adequate predictive value for identifying those in the PCG (area under the curve [AUC] = 0.534; 95% CI, 0.463-0.605; p = 0.4256); sCD14 also had poor predictive value but high specificity (100%) for identifying those in the PCG (AUC = 0.627; 95% CI, 0.556-0.694; p = 0.0036). Conclusions: While low levels of these two biomarkers were detected among those with the IHIV-1 pattern, they were found in high levels among those in the PCG. These two markers obviously cannot be used as a sceening test because they have low sensitivies. Taken together, we suggest that neopterin and sCD14 may be helpful because they both have high specificity (92%-100%) as indirect non-specific markers for predicting the immune activation status of individuals, whether or not they have true positive HIV-1.
  • PublicationOpen Access
    Clostridium difficile Colonization Before and After Hospitalization in Children
    (2021-11-01T00:00:00Z) Rzayev, Turkay; YÜKSEL MAYDA, PELİN; ERKAN, Tülay; KOCAZEYBEK, Bekir Sami; KUTLU, Hüseyin Tufan; YÜKSEL MAYDA, PELİN
    Background: Beginning in the early 2000s, Clostridium difficile infection has become a major health problem in the United States, Canada, and in most European countries and has not only increased in incidence but also the severity. There are 2 conditions for the development of C. difficile infection: disruption of the normal gastrointestinal flora, and exogenous ingestion of the microorganism. We aimed to study C. difficile colonization in hospitalized children. We identified 2 issues: (1) the relationship between risks before hospital admission and colonization on the first day of hospitalization and (2) the effect of the factors that patients are exposed to during hospitalization on the colonization status at discharge. Methods: Patients aged between 2 and 18 years who were hospitalized with various diagnoses were included in this study. C. difficile toxin A/B was investigated in the stool samples taken on the admission and discharge days. Results: One hundred six patients were included in the study, of whom 24.5% and 48.1% of hemato-oncology patients were positive for C. difficile toxin A/B. Antibiotic usage within 1 month preceding hospitalization and the presence of underlying disease impact the C. difficile colonization status on the first day of hospitalization. Conclusion: Toxigenic C. difficile colonization prevalence is high in hospitalized children, especially in the hemato-oncology patient group.
  • PublicationOpen Access
    Diagnostic performance of the RT-qPCR method targeting 85B mRNA in the diagnosis of pulmonary Mycobacterium tuberculosis infection
    (2018-09-01T00:00:00Z) Demirci, Mehmet; Saribas, Suat; Ozer, Nigar; TOPRAK, Sezer; CAGLAR, Emel; ORTAKOYLU, Gonenc; Yuksel, PELİN; Ayaz, Gulsel; Tokman, Hrisi B.; Uysal, Omer; Dinc, HARİKA ÖYKÜ; ZİVER, Tevhide; Kocazeybek, Bekir; YÜKSEL MAYDA, PELİN; UYSAL, ÖMER; DİNÇ, HARİKA ÖYKÜ
    Background: Several nucleic acid amplification techniques (IS6110, 16S rRNA, and 85B mRNA) were developed for the rapid, direct detection of Mycobacterium tuberculosis. We aimed to assess the diagnostic performance of 85B mRNA-based RT-qPCR by comparing with the real-time PCR COBAS TagMan MTB Kit while using the BACTEC MGIT 960 method as the gold standard.
  • PublicationOpen Access
    History of Epidemics and COVID-19
    (2020-12-01T00:00:00Z) YÜKSEL MAYDA, PELİN; DİNÇ, HARİKA ÖYKÜ
    In archaeological excavations, it has been reported that formations resembling bacterial fossils are found among the rock layers and they belong to millions of years ago. There are those who have created the flora and preserved us by creating our flora, and those that have brought us to the end, as well as those that help us to form the microorganisms that we share with the same planet, whose existence dates back to ancient times. Although our immune system and medical facilities are trump cards against microorganisms living in the world for much longer than human beings, these are not always enough to protect us, and microorganisms are causing outbreaks that will make history. In this review, we aimed to examine the epidemic diseases experienced by human beings from past to present and their effects.
  • PublicationOpen Access
    SARS CoV-2 Pathogenesis and Immune Response
    (2020-12-01T00:00:00Z) Dinç, Harika Öykü; Yüksel Mayda, Pelin; DİNÇ, HARİKA ÖYKÜ; YÜKSEL MAYDA, PELİN
    The agent responsible for the epidemic that first appeared in Wuhan, China, in December 2019 was detected to be the new coronavirus (2019-nCoV). Later, the virus that caused respiratory tract infection was discovered to be a member of the beta-coronavirus family, it was named as severe acute respiratory syndrome-CoV2 (SARS-CoV 2), and the disease it caused was called CoV infection disease-19 (COVID-19). The epidemic started in China, spread rapidly first to East Asian countries, then Europe and America, affected the whole world, and was declared a pandemic by the World Health Organization. This review presents an overview of SARS-CoV2 and aims to examine its intracellular pathogenesis and host immune responses.